Arcutis Biotherapeutics has a lofty goal for 2025 — and it could help Arcutis stock continue a massive run that helped shares ...

This can cause the immune response that leads to eczema symptoms. Some specific problems with a part of the immune system called the adaptive immune system probably also contribute to the disease.

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

Dupixent is already approved in the US for a variety of indications, going back to eczema in 2017 (and most recently for the treatment of the rare skin condition prurigo nodularis), but its ...

That has allowed me to get treatment that has eliminated ... drugs for psoriasis coming out all the time, but Dupixent is the first drug for eczema, and we need more. Meanwhile, a lot of ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...

If you’re prone to eczema, you don’t want to take any chances with the products you use on your skin—so washing your face ...

The phase 3 DELTA TEEN trial evaluating Anzupgo 20 mg/g cream for the treatment of chronic hand eczema in adolescents has ...

If you suffer from frequent eczema flare-ups ... condition could involve looking at family history (including previous treatments for skin-related symptoms), sleep patterns, exposure to irritants ...

Pharmaceutical ads are difficult to avoid in American television programming and a growing number of them promote a class of ...